CompanyGraph
Lineage Cell Therapeutics Inc.
LCTX · NYSE Arca · United States
lineagecell.comFinancials as of FY2025
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $260.49M, lower than 95% of all stocks globally
- PositionGross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
260.49MUSDvs all stocks (USD)
Revenue (TTM)
13.08MUSDvs all stocks (USD)
Profit Margin
-246.58%vs Biotechnology peers
Beta
1.55xvs all stocks
52-Week Change
-42.46%vs all stocks
Market Capitalization
260.49MUSDvs all stocks (USD)
Enterprise Value
210.85MUSDvs all stocks (USD)
Forward P/E
-10.10xvs Biotechnology peers
Price to Sales (TTM)
19.91xvs Biotechnology peers
Price to Book (MRQ)
4.27xvs Biotechnology peers
Enterprise to Revenue
16.12xvs Biotechnology peers
Enterprise to EBITDA
-8.07xvs Biotechnology peers
Gross Margin
100.00%vs Biotechnology peers
Profit Margin
-246.58%vs Biotechnology peers
Operating Margin
-834.70%vs Biotechnology peers
Return on Assets (TTM)
-17.04%vs Biotechnology peers
Return on Equity (TTM)
-60.06%vs Biotechnology peers
Revenue (TTM)
13.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0540USDUpdated Sep 27, 2026Quarterly Revenue Growth
-61.30%vs Biotechnology peers
Gross Profit (TTM)
-7.50MUSDvs all stocks (USD)
EBITDA (TTM)
27.36MUSDvs all stocks (USD)
Net Income (TTM)
-32.26MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-61.34%vs Biotechnology peers
Operating Cash Flow (TTM)
-23.82MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.77MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-1.20MUSDFY2025 · Dec 31, 2025Revenue
14.56MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
146.00KUSDFY2025 · Dec 31, 2025Gross Profit
14.41MUSDFY2025 · Dec 31, 2025Operating Income
-21.78MUSDvs all stocks (USD)
Pre-tax Income
-68.65MUSDFY2025 · Dec 31, 2025Income Tax Expense
-5.28MUSDFY2025 · Dec 31, 2025Net Income
-63.37MUSDFY2025 · Dec 31, 2025EBIT
-21.78MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
27.36MUSDFY2025 · Dec 31, 2025Research & Development
17.73MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
18.46MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.69MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.2800USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.2800USDFY2025 · Dec 31, 2025Basic Shares Outstanding
230.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
230.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-63.37MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-166.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
-69.54MUSDFY2025 · Dec 31, 2025Free Cash Flow
-70.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
41.32MUSDFY2025 · Dec 31, 2025Interest Paid
29.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-63.37MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
699.00KUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-5.28MUSDFY2025 · Dec 31, 2025Stock-based Compensation
4.75MUSDFY2025 · Dec 31, 2025Other Non-cash Items
81.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-316.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.11MUSDFY2025 · Dec 31, 2025Capital Expenditures
-522.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-14.94MUSDFY2025 · Dec 31, 2025Sale of Investments
2.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-13.46MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-59.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-16.00KUSDFY2025 · Dec 31, 2025Other Financing Charges
-684.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
25.38MUSDFY2025 · Dec 31, 2025Shares Outstanding
252.91MSharesUpdated Sep 27, 2026Float Shares
190.90MSharesUpdated Sep 27, 2026Shares Short
29.47MSharesUpdated Sep 27, 2026Short Ratio
29.90daysvs all stocks
Short % of Shares Outstanding
19.33%vs all stocks
% Held by Insiders
4.86%vs all stocks
% Held by Institutions
48.20%vs all stocks
Total Cash (MRQ)
50.83MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2010USDUpdated Sep 27, 2026Total Debt (MRQ)
2.30MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0384xvs Biotechnology peers
Current Ratio (MRQ)
6.61xvs Biotechnology peers
Book Value per Share (MRQ)
0.2410USDUpdated Sep 27, 2026Total Assets
112.58MUSDvs all stocks (USD)
Total Current Assets
59.16MUSDFY2025 · Dec 31, 2025Total Liabilities
69.24MUSDFY2025 · Dec 31, 2025Total Non-current Assets
53.43MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
57.87MUSDFY2025 · Dec 31, 2025Total Current Liabilities
11.37MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
40.79MUSDFY2025 · Dec 31, 2025Other Short-term Investments
14.99MUSDFY2025 · Dec 31, 2025Accounts Receivable
891.00KUSDFY2025 · Dec 31, 2025Accounts Payable
2.34MUSDFY2025 · Dec 31, 2025Short-term Debt
853.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
3.33MUSDFY2025 · Dec 31, 2025Long-term Debt
1.57MUSDFY2025 · Dec 31, 2025Common Stock (Book)
515.47MUSDFY2025 · Dec 31, 2025Retained Earnings
-467.00MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
43.35MUSDvs all stocks (USD)
52-Week Low
0.9100USDUpdated Sep 27, 202652-Week High
2.09USDUpdated Sep 27, 202652-Week Change
-42.46%vs all stocks
Beta
1.55xvs all stocks
50-Day MA
1.08USDUpdated Sep 27, 2026200-Day MA
1.42USDUpdated Sep 27, 2026Avg 10-Day Volume
1.81MSharesUpdated Sep 27, 2026Avg 30-Day Volume
1.22MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-0.1900USDUpdated Sep 27, 2026Other Income / Expense
-48.57MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 100%, higher than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 1.00Industry median: 0.67Industry P95: 1.00Peers compared: 260
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 19.91Revenue Growth YoY: -0.61
High gross margins eroded by operating costsNotable
Gross Margin: 1.00Profit Margin: -2.47
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 6.61Altman Z-Score: -3.55
Financial Health
Altman Z-Score -3.55: distress zoneCritical
Altman Z-Score: -3.55
High structural barrier to entryNotable
Barrier to Entry: 6.21
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $260.49M, lower than 95% of all stocks globallySignificant
Market cap (USD): 260,494,687Global P5: 275,556,405.438
Revenue is $13.08M, lower than 95% of all stocks globallySignificant
Revenue (USD): 13,083,000Global P5: 33,357,653.812
Companies that share the same coordination system — how they create, deliver, or capture value.
Tanvex Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Oryzon Genomics S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
TriSalus Life Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Greenwich LifeSciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ginwa Enterprise Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
PharmaEngine, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Nucien Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Daito Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Mesoblast Limited
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Acimmune SA
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
XTL Biopharmaceuticals Ltd.
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC